Third Quarter 2018 Report
October 22, 2018
20/20's SEC Qualified Reg. A+ Campaign Exceeds $3 Million Invested to Date
On August 16, the U.S. Securities & Exchange Commission Qualified our offering under Regulation A. Since our campaign went live on the SeedInvest portal during the last week of August, we have closed on over $3 million from nearly 800 investors in about 2 months. This follows the $1 million we raised at the end of 2017 under Reg. CF. If our offering continues at this pace through the end of 2018, we could become the top equity crowdfunding biotech company in the U.S.

There are several advantages of investing in a Reg. A+ offering (vs. a traditional private placement) for both individuals and institutional investors. These include more transparency and potentially earlier liquidity by accessing the public markets. For more on this, please read " Three Big Advantages of Investing in a Reg. A+ Qualified Company ".

Please invite your colleagues to consider making an investment by visiting our crowdfunding portal before our campaign concludes.
maryland flag_ 3D rendering_ on a cloud background
Guaranteed State Refunds (50% of Investment) Await New Investors 
The Maryland Biotechnology Investor Tax Credit has for many years provided a more than 50% cash refund to over 200 investors in our company. Most of these investors reside outside of Maryland. This year, we were successful in advancing to the front of the state's online application queue resulting in $2 million in investments guaranteed to receive the state & county 50% cash refund. Of this amount, we have already closed on $1.5 million, have soft commitments for another $150,000, leaving room for another $350,000 in refundable investments.

As is clear from this official Initial Tax Credit Certificate, these investments must close over the next 20 days to qualify.

If you are interested in making a new investment with a guaranteed 50% refund, please contact Richard Greene no later than Oct. 29 at or 301-455-5676.
OneTest promotional signage at a suburban Washington, D.C. shopping mall has generated several online orders
OneTest e-commerce site now live; 30 tests ordered over first 3 weeks
At the start of October, our OneTest website went live enabling consumers to learn about the product and purchase our specimen collection kit which they can take to their doctor. Since then, we have received about 1-2 purchases per day despite very minimal promotional efforts. Increased sales and marketing efforts are being kicked off in the 4th quarter.

Crowdfund investors entitled to complimentary tests and other 20/20 shareholders interested in a 50% discount should contact Careen at or 240-453-6339 x105 to receive a discount code.

BioCheck Sales Up 70% Year-to-Date. Now Cross-Selling w/ OneTest for Fire Fighters
For many years, 20/20's patented BioCheck kits have been the first tool used by hundreds of fire departments and other emergency response organizations around the world when confronting suspicious powders feared to potentially contain a deadly bio-threat agent. Over the first 3 quarters of 2018, revenues for this product were up 70% from the same period last year.

Leveraging our strong positive brand identification among the hazardous materials segment of the fire service, a population with proven higher cancer rates according to a recent government report, we have begun to successfully sell OneTest to our BioCheck customers and distributors most recently at the HotZone Hazmat conference in Houston.

The results of this initiative should be included in our year-end report. 
Word writing text We re Hiring. Business concept for Recruiting Hiring Now Recruitment Vacancy Announced Hire written Notebook Paper the jute background Marker and Mouse next to it.
20/20 Hiring New Sales Representatives
We plan to hire up to 5 new Sales & Marketing representatives by the end of October. To date, over 50 resumes have been received resulting in ten interviews.

Additional hires in R&D (data science) and Business Development are expected by year-end.
In case you missed... Please click below to download 
Regulation A
20/20 GeneSystems is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. The Final Offering Circular that forms a part of the Offering Statement may be downloaded here:
Investing in an initial public offering under Regulation A is subject to unique risks, tolerance for volatility, and potential loss of principal, that customers should be aware of prior to making an investment decision. For more information about Regulation A offerings, including the unique risks associated with these types of offerings, please click on the SEC's Reg. A Investor Bulletin .

Forward-Looking Statements
Some of the statements in this document including statements regarding a future offering of the Company's securities under Regulation A, the potential success of any such offering, and the Company's ability to successfully sell and commercialize its cancer diagnostic products, constitute forward-looking statements. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends, and similar matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "potential", "should", "will" and "would" or the negatives of these terms or other comparable terminology.
You should not place undue reliance on forward looking statements. The cautionary statements set forth in the Form 1-A with the SEC in March 2018, including in "Risk Factors" and elsewhere therein, identify important factors which you should consider in evaluating our forward-looking statements. 
Although the forward-looking statements in this document are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements, or outcomes. No assurance can be made that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. We undertake no obligation, other than as may be required by law.